Roberto Martinez Quintana, MD
Pulmonary Disease · San Juan, PRNPI 1023007523
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.1%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Merck at 42.8% of the total. Reporting peaked in 2021 at $4,143 and has fallen 65.0% since, to $1,449 in 2025. Among pulmonary disease clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 203 payments — averaging $61.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$5K
- Sanofi$2K
- AstraZeneca$2K
- GSK$942
- Boehringer Ingelheim$587
- Amgen$308
- plus $1K from 14 others
What the payments were for
- Consulting fees$5,44144%
- Speaking & faculty fees$1,50012%
- Food & beverage$5,47544%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 7 | $5,318 |
| Sanofi | 12 | $2,249 |
| AstraZeneca | 74 | $1,946 |
| GSK | 39 | $942 |
| Boehringer Ingelheim | 25 | $587 |
| Amgen | 12 | $308 |
| Jazz Pharmaceuticals Inc. | 4 | $215 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $173 |
| Mylan Specialty L.p. | 5 | $111 |
| Johnson & Johnson | 5 | $108 |
| E.r. Squibb & Sons, L.L.C. | 4 | $97 |
| Mylan LLC | 3 | $68 |
| Genentech USA, Inc. | 1 | $67 |
| Eli Lilly Export S.A. Puerto Rico Branch | 2 | $50 |
| Harmony Biosciences LLC | 2 | $50 |
| United Therapeutics Corporation | 1 | $35 |
| Viatris Specialty LLC | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| PBG Puerto Rico LLC | 1 | $21 |
| Pfizer Pharmaceuticals LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$1,961
- PNEUMOVAX 23$1,500
- FASENRA$226
- GLASSIA$123
- BREZTRI$121
How this compares
$12,416 in reported general payments places this provider in the 90th percentile of 138 pulmonary disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fasenra PenBenralizumab | 19 | $108,819 |
| FasenraBenralizumab | 15 | $86,352 |
| Spiriva RespimatTiotropium Bromide | 100 | $53,231 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $30,478 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $26,105 |
| Fluticasone Propionate HfaFluticasone Propionate | 85 | $25,961 |
| Qvar RedihalerBeclomethasone Dipropionate | 49 | $14,004 |
| SymbicortBudesonide/Formoterol Fumarate | 58 | $13,827 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $11,568 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 281 | $11,313 |
| Montelukast Sodium | 656 | $9,616 |
| Wixela InhubFluticasone Propion/Salmeterol | 51 | $8,745 |
| Advair HfaFluticasone Propion/Salmeterol | 24 | $8,606 |
| SynthroidLevothyroxine Sodium | 50 | $5,718 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $5,616 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFasenra, Symbicort, Breztri Aerosphere | $1,946 | $111,74791 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $942 | $59,282110 claims |
| Boehringer IngelheimSpiriva Respimat | $587 | $53,231100 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $25 | $14,00449 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 138 pulmonary disease providers in Puerto Rico.
Other pulmonary disease in San Juan
- Joel Nieves ScharonSan Juan$43K
- Luis Gerena MontanoSan Juan$15K
- Rafael Franjul JuliaoSan Juan$15K
- Sandra Rosario LebronSan Juan$11K
- Juan Malpica-SantiagoSan Juan$11K
- Daphne Delgado PerezSan Juan$10K
- Maximo Blondet PassalacquaSan Juan$8K
- Pedro Monroig QuilesSan Juan$6K
- Marieliz Alvarado DavilaSan Juan$6K
- Edgar Rodriguez GonzalezSan Juan$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.